{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:06:18Z","timestamp":1792386378096,"version":"4.4.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamadermatol.2020.0079","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:31:27Z","timestamp":1582716687000},"page":"411","source":"Crossref","is-referenced-by-count":328,"title":["Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"156","author":[{"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Principal Investigator and President, Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Diego"},{"name":"Department of Pediatrics, University of California, San Diego"},{"name":"Pediatric and Adolescent Dermatology, Rady Children\u2019s Hospital, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Drew","sequence":"additional","affiliation":[{"name":"Dermira, Inc, Menlo Park, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanan","family":"Gopalan","sequence":"additional","affiliation":[{"name":"Dermira, Inc, Menlo Park, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi200006r1","first-page":"1061","article-title":"Biological therapies for atopic dermatitis: an update.","volume":"17","author":"Deleanu","year":"2019","journal-title":"Exp Ther Med"},{"issue":"2","key":"doi200006r2","first-page":"83","article-title":"The challenge of managing atopic dermatitis in the United States.","volume":"12","author":"Feldman","year":"2019","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"doi200006r3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: clinical implications.","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"doi200006r4","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e42","article-title":"From bench to clinic: the potential of therapeutic targeting of the IL-22 signaling pathway in atopic dermatitis.","volume":"18","author":"Jin","year":"2018","journal-title":"Immune Netw"},{"issue":"4S","key":"doi200006r5","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"doi200006r6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.2019.28.issue-7","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches.","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"issue":"3","key":"doi200006r7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/pai.2012.23.issue-3","article-title":"IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis.","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"doi200006r8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis.","volume":"122","author":"Raap","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi200006r9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jdv.2011.25.issue-3","article-title":"Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring.","volume":"25","author":"Ezzat","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi200006r10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch.","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"doi200006r11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.v75.1","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis.","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"doi200006r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics.","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"doi200006r13","doi-asserted-by":"publisher","first-page":"B8","DOI":"10.1016\/j.jid.2018.06.042","article-title":"Neuronal responses elicited by interleukin-13 in human neurons.","volume":"138","author":"Miron","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi200006r14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease.","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"11","key":"doi200006r15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00403-004-0455-6","article-title":"Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis.","volume":"295","author":"Tazawa","year":"2004","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"doi200006r16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaci.2012.06.044","article-title":"Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.","volume":"130","author":"Choy","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi200006r17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/all.2005.60.issue-3","article-title":"CD4+IL-13+ cells in peripheral blood well correlates with the severity of atopic dermatitis in children.","volume":"60","author":"La Grutta","year":"2005","journal-title":"Allergy"},{"issue":"1","key":"doi200006r18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population.","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"doi200006r19","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases.","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi200006r20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.","volume":"144","author":"Zhou","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi200006r21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti\u2013IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE).","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"doi200006r24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"doi200006r27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis.","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"issue":"92","key":"doi200006r28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis.","volume":"60","author":"Hanifin","year":"1980","journal-title":"Acta Dermatovener (Stockholm) Suppl"},{"issue":"1","key":"doi200006r29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association.","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi200006r30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.iac.2016.08.007","article-title":"Itch in atopic dermatitis.","volume":"37","author":"Kido-Nakahara","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"doi200006r31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.det.2017.02.011","article-title":"Adjunctive management of itch in atopic dermatitis.","volume":"35","author":"Elmariah","year":"2017","journal-title":"Dermatol Clin"},{"issue":"24","key":"doi200006r33","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"doi200006r34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"doi200006r35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb.","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"doi200006r36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis.","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi200006r37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing.","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"doi200006r38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2\/TH1 cell imbalance, whereas adults acquire CLA+ TH22\/TC22 cell subsets.","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi200006r39","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"doi200006r40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jaad.2019.04.036","article-title":"The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.","volume":"81","author":"Brunner","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi200006r41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.anai.2019.10.013","article-title":"Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis.","volume":"124","author":"He","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"doi200006r42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma.","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"doi200006r43","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"issue":"1","key":"doi200006r44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/cea.12220","article-title":"The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.","volume":"44","author":"Scheerens","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"doi200006r45","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.","volume":"132","author":"Noonan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"doi200006r46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"doi200006r48","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdv.2019.33.issue-7","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy: International Eczema Council survey and opinion.","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi200006r49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi200006r50","doi-asserted-by":"publisher","first-page":"12162","DOI":"10.1038\/s41598-018-30002-x","article-title":"Context-dependent regulation of conjunctival goblet cell function by allergic mediators.","volume":"8","author":"Garc\u00eda-Posadas","year":"2018","journal-title":"Sci Rep"},{"key":"doi200006r51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","article-title":"T helper cytokines in dry eye disease.","volume":"117","author":"Pflugfelder","year":"2013","journal-title":"Exp Eye Res"},{"issue":"8","key":"doi200006r52","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells.","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"doi200006r53","article-title":"Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: a multi-institution retrospective chart review","author":"Waldman","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi200006r54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis.","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"doi200006r55","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","author":"Nahum","journal-title":"Br J Ophthalmol"},{"issue":"10086","key":"doi200006r56","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"doi200006r57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis.","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"doi200006r58","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis.","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi200006r59","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.2019.180.issue-5","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200006r60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in atopic dermatitis patients stratifies tissue responses to fezakinumab.","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"doi200006r32","year":"2017"},{"key":"doi200006r22","unstructured":"US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/media\/77832\/download. Published December 2009. Accessed November 27, 2017."},{"key":"doi200006r23","unstructured":"Office of Medical Products and Tobacco, Center for Drug Evaluation and Research; Office of Medical Products and Tobacco, Center for Biologics Evaluation and Research. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6 (R1). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1. Published February 2018. Accessed March 7, 2018."},{"key":"doi200006r25","unstructured":"ClinicalTrials.gov. Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis. NCT04146363. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146363?cond=NCT04146363&draw=2&rank=1. Accessed January 18, 2020."},{"key":"doi200006r26","unstructured":"ClinicalTrials.gov. Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis. NCT04178967. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04178967?cond=NCT04178967&draw=2&rank=1. Accessed January 18, 2020."},{"key":"doi200006r47","unstructured":"ClinicalTrials.gov. A study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with atopic dermatitis. NCT02465606. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02465606?term=NCT02465606&rank=1. Accessed November 15, 2019."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2761466\/jamadermatology_guttmanyassky_2020_oi_200006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T14:01:21Z","timestamp":1695823281000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2761466"}},"subtitle":["A Phase 2b Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}